PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.73%
R&D reduction while AVXL shows 29.60% growth. Joel Greenblatt would examine competitive risk.
3.54%
G&A growth less than half of AVXL's 18.88%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
-10.44%
Operating expenses reduction while AVXL shows 27.25% growth. Joel Greenblatt would examine advantage.
-10.44%
Total costs reduction while AVXL shows 27.25% growth. Joel Greenblatt would examine advantage.
-100.00%
Interest expense reduction while AVXL shows 0.00% growth. Joel Greenblatt would examine advantage.
721.68%
D&A growth less than half of AVXL's 26090.22%. David Dodd would verify if efficiency is sustainable.
11.90%
EBITDA growth below 50% of AVXL's 100.00%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
10.44%
Operating income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-34.01%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
10.28%
Pre-tax income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.28%
Net income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
12.12%
EPS growth while AVXL declines. John Neff would investigate advantages.
10.49%
Diluted EPS growth while AVXL declines. John Neff would investigate advantages.
2.21%
Share count reduction below 50% of AVXL's 1.76%. Michael Burry would check for concerns.
No Data
No Data available this quarter, please select a different quarter.